



Editorial comment

Complex role of peroxisome proliferator activator receptors (PPARs) in nociception

Rashid Giniatullin^{a,b,*}, Geneviève Bart^a, Pasi Tavi^a^a A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniementie 2, Kuopio 70211, Finland^b Open Laboratory of Neurobiology, Institute of Fundamental Biology and Medicine, Kazan Federal University, Kremlevskaya Street 18, Kazan 420008, Russia

1. Peroxisome proliferator activator receptor (PPAR) signalling

In this issue of the *Scandinavian Journal of Pain*, Okine et al. report the analgesic action of the synthetic peroxisome proliferator activator receptor- α (PPAR α) agonist WY-14643 on nociceptive spinal neuronal firing in a rodent model of neuropathic pain [1]. The search for an efficient treatment of neuropathic pain has been rather challenging and the demonstration that new targets can be found is very encouraging. PPAR α is a very promising target because contrary to many other anti-nociceptive treatments, its activation does not seem to be associated with any undesirable effect but rather is linked to several more broad benefits. It has been for instance, associated with lowering of inflammation [2], and improvement of cognitive functions in models of cognitive impairment [3]. Moreover, it was also shown not to induce tolerance, which is a common problem in chronic pain treatment [4].

The peroxisome proliferator-activated receptors (PPARs) are nuclear receptors best characterized for their actions in metabolism and oxidative stress regulation. The PPAR family includes PPAR α , PPAR β/δ and PPAR γ all of which are expressed at different levels by microglia, astrocytes, neurons and oligodendrocytes [5]. PPARs heterodimerize with the Retinoid X receptor to bind DNA on the PPAR response element (PPRE) and initiate gene transcription [6], several co-factors like PGC1- α , CBP/p300, SERC1 are necessary for further fine-tuning of tissue-specific effects. PPRE is highly conserved in different species, suggesting a fundamental role for the pathways it activates in a variety of fundamental biological processes. In addition to these genomic effects, receptor-like almost instantaneous responses (within minutes), independent of gene activation have also been described (reviewed in [7]), consistent with the earlier finding that a fraction of the PPAR α proteins is located at the cell

membrane [8]. This novel observation added even more complexity to the previous canonical vision on genomic PPAR signalling.

The field of PPAR signalling has been rapidly expanding following the discoveries of endogenous ligands and the development of new subtype specific agonists but, till recently, it has been mostly directed to the study of metabolic and vascular disorders [9].

2. PPAR α in nociception

It has been found recently that PPAR α also plays an important anti-nociceptive role in the nervous system [4], which is clearly demonstrated in PPAR α knockout mice, by their enhanced sensitivity to a range of noxious and mechanical stimuli in neuropathic pain models [10].

This likely implies that PPAR α is an activator of endogenous pathways involved in limiting excessive pain signalling. The endogenous PPAR α agonist palmitoylethanolamide is able to activate and subsequently desensitize the pain transducing TRPV1 channels in the peripheral nociceptive sensory neurons [11]. This study and others also suggests that the anti-nociceptive effect is mediated via the rapid, non-genomic PPAR α signalling pathway. All these data present PPAR α as a multifaceted candidate pathway for the fine-tuning of pain control. To date, much attention was paid to the role of PPAR in primary sensory neurons (peripheral nociception), which express a plethora of pain transducing molecules such as heat and capsaicin activated TRPV1 receptors.

Recent study by Okine et al. [1] adds new support for the role of PPAR α in pain control and identifies novel spinal targets for pain processing. The authors show that intraperitoneal administration of the synthetic PPAR α agonist WY-14643 attenuated key symptoms of neuropathic pain in rats. The authors also obtained original data suggesting, unlike previous views on the peripheral role of PPAR α [8], the involvement of spinal neurons in nociceptive signal processing in spinal nerve ligation model of neuropathic pain. The principal significance of the latter relies on the rationale route of drug administrations to counteract spinally located neuropathic pain. Effective systemic administration of analgesic drugs targeting central or spinal neurons normally protected by the brain–blood barrier has an obvious advantage over intrathecal delivery. The synthetic PPAR α agonist WY-14643 used in this study is also

DOI of refers to article: <http://dx.doi.org/10.1016/j.sjpain.2015.06.004>.

* Corresponding author at: A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniementie 2, Kuopio 70211, Finland.

Tel.: +358 403553665; fax: +358 17163030.

E-mail address: rashid.giniatullin@uef.fi (R. Giniatullin).

offering hope for other challenging pathologies like Alzheimer disease, epilepsy and neuroinflammation as it was shown to counteract A β -42 toxicity in neurons [12], to prevent nicotine-induced seizure [13] and to modulate infection [14] and stroke-induced neuroinflammation [15].

The new data by Okine et al. provide a better understanding of the multicomponent signalling pathways in chronic pain by its identification of a novel location of PPAR α receptors mediated anti-nociception at the level of spinal cord. Moreover, they suggest a practical pharmacologic approach and spinal targets for the pain management. Importantly, this is done with the chronic neuropathic pain, which is often resistant to common analgesic treatments.

3. Conclusion and implications

The study of Okine et al. [1] presents a novel aspect of the anti-nociception mediated by the synthetic PPAR α agonist at the level of spinal cord in the rodent model of the neuropathic pain. The findings highlight the role of the spinal nociceptive network employing PPARs in pain processing. While promising data were obtained here in the rodent model, optimization of the pharmacokinetics and pharmacodynamics along with chemical design/improvement of this or similarly acting PPAR agonists is required, however, on the long way to clinical use of these agents.

Conflict of interest

No conflict of interest declared.

References

- [1] Okine BN, Spicer C, Milns P, Bennett A, Chapman V. Systemic administration of WY-14643 a selective synthetic agonist of peroxisome proliferator activator receptor-alpha alters spinal neuronal firing in a rodent model of neuropathic pain. *Scand J Pain* 2015;9:42–8.
- [2] Hecker M, Behnk A, Morty RE, Sommer N, Vadász I, Herold S, Seeger W, Mayer K. PPAR- α activation reduced LPS-induced inflammation in alveolar epithelial cells. *Exp Lung Res* 2015;7:1–11.
- [3] D'Agostino G, Cristiano C, Lyons DJ, Citraro R, Russo E, Avagliano C, Russo R, Raso GM, Meli R, De Sarro G, Heisler LK, Calignano A. Peroxisome proliferator-activated receptor alpha plays a crucial role in behavioral repetition and cognitive flexibility in mice. *Mol Metab* 2015;4:528–36.
- [4] LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. *J Pharmacol Exp Ther* 2006;319:1051–61.
- [5] Mandrekar-Colucci S, Sauerbeck A, Popovich PG, McTigue DM. PPAR agonists as therapeutics for CNS trauma and neurological diseases. *ASN Neuro* 2013;5:e00129.
- [6] Tzeng J, Byun J, Park JY, Yamamoto T, Schesing K, Tian B, Sadoshima J, Oka S. An ideal PPAR response element bound to and activated by PPAR α . *PLOS ONE* 2015;10:e0134996.
- [7] Fehrenbacher JC, Loverme J, Clarke W, Hargreaves KM, Piomelli D, Taylor BK. Rapid pain modulation with nuclear receptor ligands. *Brain Res Rev* 2009;60:114–24.
- [8] Ropero AB, Juan-Picó P, Rafacho A, Fuentes E, Bermúdez-Silva FJ, Roche E, Quesada I, de Fonseca FR, Nadal A. Rapid non-genomic regulation of Ca²⁺ signals and insulin secretion by PPAR alpha ligands in mouse pancreatic islets of Langerhans. *J Endocrinol* 2009;200:127–38.
- [9] Moran EP, MajX. Therapeutic effects of PPAR α on neuronal death and microvascular impairment. *PPAR Res* 2015;2015:595426.
- [10] Ruiz-Medina J, Flores JA, Tasset I, Tunez I, Valverde O, Fernandez-Espejo E. Alteration of neuropathic and visceral pain in female C57BL/6J mice lacking the PPAR- α gene. *Psychopharmacology (Berl)* 2012;222:477–88.
- [11] Ambrosino P, Soldovieri MV, Russo C, Tagliatela M. Activation and desensitization of TRPV1 channels in sensory neurons by the PPAR α agonist palmitoylethanolamide. *Br J Pharmacol* 2013;168:1430–44.
- [12] Cheng YH, Lai SW, Chen PY, Chang JH, Chang NW. PPAR α activation attenuates amyloid- β -dependent neurodegeneration by modulating Endo G and AIF translocation. *Neurotox Res* 2015;27:55–68.
- [13] Puligheddu M, Pillolla G, Melis M, Lecca S, Marrosu F, De Montis MG, Scheggi S, Carta G, Murru E, Aroni S, Muntoni AL, Pistis M. PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings. *PLOS ONE* 2013;8:e64541.
- [14] Wang G, Namura S. Effects of chronic systemic treatment with peroxisome proliferator-activated receptor α activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice. *Neurosci Res* 2011;70:230–7.
- [15] Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiemermann C, Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. *Eur J Pharmacol* 2006;530:70–80.